Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8878519 | 0.98 | PTGS1 (0.96) | PTGS1PTGS2RAB9ANPC1MAPT | |
| Bromide SCHEMBL570786 | 0.98 | PTGS1 (0.96) | PTGS1PTGS2RAB9ANPC1MAPT | |
| Water SCHEMBL21708935 | 0.98 | PTGS1 (0.96) | PTGS1PTGS2RAB9ANPC1MAPT | |
| SCHEMBL2334973 | 0.98 | PTGS1 (0.96) | PTGS1PTGS2RAB9ANPC1MAPT | |
| SCHEMBL1728538 | 0.84 | PTGS1 (0.73) | PTGS1PTGS2RAB9ANPC1MAPT | |
| SCHEMBL7929884 | 0.84 | PTGS1 (0.72) | PTGS1PTGS2RAB9ANPC1MAPT | |
| SCHEMBL174711 | 0.84 | PTGS1 (0.72) | PTGS1PTGS2RAB9ANPC1MAPT | |
| SCHEMBL2524283 | 0.84 | PTGS1 (0.72) | PTGS1PTGS2RAB9ANPC1MAPT | |
| SCHEMBL15924280 | 0.83 | MAPT (0.72) | PTGS1PTGS2RAB9ANPC1MAPT | |
| Lithium Ion SCHEMBL2334977 | 0.82 | PTGS1 (0.70) | PTGS1PTGS2RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| EP-3953353-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-02-16 | — | — | EP | claimed |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | claimed |
| EP-2906581-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| WO-2014056748-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| US-8461160-B2 | Dihydropyrimidinones | HOFFMANN-LA ROCHE, INC. (US) | 2013-06-11 | — | — | US | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| JP-2011529057-A | — | — | 2011-12-01 | — | — | JP | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | claimed |
| WO-2010011570-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | WO | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| EP-1651647-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDEA4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | claimed |
| US-20060084806-A1 | Processes for the preparation of imidazo[1,2-a] pyridine derivatives | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2005010001-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDEA4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | PTGS1 742/4885PTGS2 559/4885RAB9A 4065/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | PTGS1 4045/4885PTGS2 3251/4885RAB9A 1227/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | PTGS1 542/4885PTGS2 709/4885RAB9A 314/4885 |
| US-20060084806-A1 | Processes for the preparation of imidazo[1,2-a] pyridine derivatives | CBR1, HNRNPA2B1, HNRNPR | PTGS1 1858/4885PTGS2 1221/4885RAB9A 1713/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | PTGS1 608/4885PTGS2 502/4885RAB9A 4204/4885 |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | PTGS1 1154/4885PTGS2 1787/4885RAB9A 1188/4885 |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | PTGS1 3537/4885PTGS2 2700/4885RAB9A 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.